Funding was co-led by B Capital and U.S. Venture Partners, according to a news release. The money will support development of personalized cervical spinal fusion implants and commercialization of aprevo lumbar fusion devices.
Aprevo has FDA breakthrough device designation for lumbar and cervical patient-specific interbody fusion devices. Carlsmed’s aprevo cervical fusion implant is expected to launch in 2025.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.